Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 81

recruiting
3 982
countries
28
conditions
2 106

2 729 trials match your criteria

Study of Avacopan Safety and Effectiveness in Patients with ANCA-associated Vasculitis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Avacopan

Psoriasis

Not yet recruiting

Study on the Effectiveness and Safety of JNJ-77242113 and Deucravacitinib for Adults with Moderate to Severe Plaque Psoriasis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib

Seasonal allergy

Not yet recruiting

Study on the Effectiveness of Beltavac with Grass Pollen Extract for Patients with Allergic Rhinoconjunctivitis and Possible Asthma

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:Placebo

Dermatitis atopic

Not yet recruiting

Study on the Effectiveness and Safety of ANB032, Hydrocortisone, and Alclometasone Dipropionate for Patients with Moderate to Severe Atopic Dermatitis

Registered drug
Countries:PolandPoland
  • Participants:18–64 years
  • Substances:ANB032

Rheumatoid arthritis

Not yet recruiting

Study on the Effectiveness and Safety of Tocilizumab and Methotrexate for Adults with Moderate to Severe Rheumatoid Arthritis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Tocilizumab

Osteoporosis postmenopausal

Not yet recruiting

Study on the Effects of BP16 and Denosumab in Women with Post-Menopausal Osteoporosis

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid

Non-small cell lung cancer

Not yet recruiting

Study on the Effects and Safety of Cemiplimab and BNT116 in Adults with Advanced Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Cemiplimab

Psoriasis

Not yet recruiting

Study on the Effectiveness of JNJ-77242113 and Deucravacitinib for Treating Moderate to Severe Plaque Psoriasis in Adults

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib

Epidermolysis bullosa

Not yet recruiting

Study on ABCB5+ MSCs for Recessive Dystrophic and Junctional Epidermolysis Bullosa Patients

Registered drug
Countries:PolandPoland
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Clemastine Fumarate

Dermatitis atopic

Not yet recruiting

Study on Rocatinlimab for Adolescents Aged 12-17 with Moderate-to-Severe Atopic Dermatitis

InvestigationalNo placebo
Countries:PolandPoland
  • Participants:0–17 years
  • Substances:Rocatinlimab

Dermatitis atopic

Not yet recruiting

Study of LY3454738 for Treating Moderate-to-Severe Atopic Dermatitis in Adults

Registered drug
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:LY3454738

Conjunctivitis allergic

Not yet recruiting

Study on the Effectiveness and Safety of PQ Birch for Patients with Seasonal Allergic Rhinitis or Rhinoconjunctivitis from Birch Pollen

Investigational
Countries:PolandPoland
  • Participants:18–64 years · 65+ years
  • Substances:Placebo
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.